Supply chain issues caused major problems for Inogen in FY22, and continued headwinds are expected in FY23. Management expects operational performance to improve in late FY23 but indicates that ...

Click to share on Facebook (Opens in new window) Click to email a link to a friend (Opens in new window) Click to print (Opens in new window) Click to share on X (Opens in new window) Inogen Inc. of ...

Inogen (INGN) came out with a quarterly loss of $0.2 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to a loss of $0.25 per share a year ago. These figures are adjusted ...

GOLETA, Calif.--(BUSINESS WIRE)--Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it will report ...

Needham analyst Mike Matson upgraded Inogen, Inc (NASDAQ:INGN) from Hold to Buy, with a price forecast of $12. On May 7, the company reported its first-quarter results. Total revenue in the quarter ...

Inogen, Inc. INGN is well-poised for growth in the coming quarters, courtesy of high prospects in the portable oxygen concentrator (POC) space. The optimism, led by solid first-quarter 2025 ...